Purpose of review Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis.
INTRODUCTION
Systemic lupus erythematosus (SLE) is characterized by a loss of self-tolerance and the development of autoantibodies to ubiquitous nuclear self-antigens. This autoAb production is initiated by exposure of the immune system to self-antigens via various mechanisms, including abnormal clearance of apoptotic material [1] . In addition, the threshold for the autoimmune response is lowered by activation of the type I interferon (IFN) pathway [2] .
SLE affects mostly women of reproductive age, with up to 20% of the cases beginning in childhood [3] . It is a potentially devastating disease, which can involve practically any organ system. Renal involvement, termed lupus nephritis, significantly increases the morbidity and mortality of SLE patients and requires aggressive immunosuppressive therapy, which unfortunately is associated with a plethora of side-effects. The lupus nephritis histology-based classification system currently in use gives the clinician a tool to predict outcomes and to tailor therapy, albeit with moderate to good success at best [4
PATHOGENESIS OF LUPUS NEPHRITIS
In recent years, we have learned a great deal about activation of B cells and their contribution to the maintenance of autoantibody production, as well as the importance of local renal expression of inflammatory cytokines promoting the influx of immune cells [5 && ]. In this section, we will mainly focus on newly identified pathogenic mechanisms contributing to the local inflammatory environment in the kidney, and to events leading to the influx, persistence, and autoAb production of long-lived plasma cells.
Plasma cells and B cells
Long-lived memory plasma cells play a central role in the production of autoantibodies and their maintenance, and can be detected in the peripheral blood of SLE patients during a disease flare [6] . However, their exact contribution to the development of SLE and lupus nephritis was unclear. Cheng et al. [7 && ] elegantly demonstrated the role of long-lived memory plasma cells in the pathogenesis of SLE by infusing plasma cells from lupus mice into Rag1 À/À mice lacking B cells and plasma cells. The infused cells homed to the spleen and bone marrow of the recipient mice, and resulted in generation of autoantibodies to double-stranded DNA and the development of immune complex nephritis within 21 weeks of the adoptive transfer. Furthermore, Espeli et al. [8] described localization of autoreactive plasma cells in the kidney, in addition to the spleen and bone marrow, of New Zealand Black x New Zealand White (NZB/W) F1 mice [9] , a lupus-prone mouse strain that develops nephritis. In fact, most immunoglobulin G (IgG) anti double-stranded DNA-specific plasma cells were found in the kidneys, followed by the bone marrow and spleen. These cells were more prevalent in mice with lupus nephritis, and were located in the tubulointerstitium. In lupus patients, plasma cells could be found in the medulla of those with the most severe kidney disease, particularly patients with combined class III/IV and V lupus nephritis. The plasma cells in the kidneys also distinguished themselves from those in lymphoid organs in that more than 90% of them were not actively undergoing cell cycle changes. The fact that most of the plasma cells in the kidneys are not dividing and are localized to the deeper areas of the kidneys may explain some of the difficulty in treating lupus nephritis with standard immunosuppression, as well as emphasizing the importance of local chemotactic factors. Further support for the centrality of B cell activation in lupus nephritis can be found in a study by Ripoll et al. [10 & ] in which CD40, a costimulatory molecule for B cell activation, was silenced by small interfering RNA (siRNA) technology in the kidneys of NZB/W F1 mice. The authors compared the clinical and histological changes in CD40-siRNA-treated mice to those receiving established treatments for lupus nephritis, such as cyclophosphamide. CD40-siRNA resulted in a decrease in influx of immune cells as well as prevention of progression comparable to the 'standard of care'.
Cytokines and chemokines are important for B cell survival and the orchestration of inflammatory cell migration. MRL/lpr mice are a mouse strain that is particularly susceptible to develop lupus nephritis [9] . In this mouse model, Moreth et al. [11] demonstrated a role for the proteoglycan biglycan in triggering CXCL13 overexpression, leading to an increased influx of B cells, worsening proteinuria, and more severe kidney damage.
Anti-B cell activating factor (BAFF) monoclonal antibody (mAb) was approved for SLE in 2011, although a specific benefit for lupus nephritis has not been demonstrated to date. In a prospective study, Sun et al. [12 & ] assessed the correlation between local expression of BAFF, localization of infiltrating CD20 þ B cells in lupus nephritis biopsies, and nephritis severity. Infiltrating B cells and intrarenal BAFF were predominantly localized in the interstitium, and both correlated with proteinuria as well as serum levels of blood urea nitrogen and creatinine. Interestingly, there was no correlation between intrarenal BAFF expression and plasma BAFF levels.
MicroRNAs (miRNAs) are small noncoding RNAs that modulate gene expression at the posttranscriptional level by binding to the 3' untranslated
KEY POINTS
There is an increasing appreciation for the contribution of interstitial autoantibody-producing long-lived plasma cells to the renal inflammation in lupus nephritis.
Epigenetic changes in lupus nephritis patients most likely contribute to disease pathogenesis, and these changes themselves and their facilitators, for example hypomethylation of T cell DNA and microRNAs, may serve as biomarkers of disease activity.
Understanding the multiple pathways contributing to lupus nephritis may eventually allow physicians to better tailor individualized therapeutic regimens, through the application of target-specific and diseasestage-specific treatment protocols.
The diagnosis and treatment of lupus nephritis Schwartz et al. region of their target, thereby affecting the translation or stability of the transcripts [13] . Emerging evidence has demonstrated that miRNAs play a vital role in autoimmunity [14, 15] and in lupus nephritis, in particular [16] . Recently, Liu et al. [17] demonstrated that (part of a specific name of a microRNA segment) (miR)-30a was significantly increased in B cells from SLE patients, and overexpressed miR-30a in vitro could lower the level of Lyn, a member of the Src family protein-tyrosine kinases, in B cells. Interestingly, Lyn-deficient mice develop an autoimmunetype disease, characterized by the development of autoantibodies in the serum and deposition of immune complexes in the kidney -pathologic features reminiscent of SLE [18] . The role of miR-15a was assessed in the IFNaccelerated NZB/W F1 model of SLE. IFN treatment elevated miR-15a levels, which in turn correlated with lower levels of regulatory B cell subpopulations, particularly B-10. The authors concluded that IFN-induced miR-15a overexpression may have a specific negative regulatory effect on this B cell subpopulation [19] .
Macrophages
Glomerular immune-complex deposition leads to the influx of multiple immune cells, including macrophages. Sialoadhesin, a sialic acid-binding immunoglobulin-like lectin, is a macrophagerestricted adhesion molecule that can be induced under the influence of IFN-a, and which serves as a biomarker for a type I IFN-signature [20] . In SLE, sialoadhesin-expressing monocytes have been shown to correlate with disease severity [21] . Sialoadhesin was also thought to have a functional component, as its deficiency leads to amelioration of murine autoimmune neuropathy [22] . However, Kidder et al. [23 ] as a biomarker for disease severity in lupus nephritis, it will not necessarily serve as a future therapeutic target.
Inflammatory cytokines
In parallel with the recognition that intrarenal inflammation has its own spectrum of immune cells, the past years have also shed more light on the roles of particular cytokines and their receptors, which have moved on to become therapeutic targets. One example is tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily. TWEAK is an inflammatory cytokine that is believed to play an important role in lupus nephritis. ]. These findings supported the development of a human anti-TWEAK antibody as an add-on treatment to the standard-of-care, a concept currently being tested in a multicenter phase II clinical trial (Anti-TWEAK in Lupus Nephritis, ClinicalTrials.gov Identifier: NCT01499355).
DIAGNOSIS AND DISEASE MONITORING
The incidence of end-stage renal disease from lupus nephritis did not change from 1996 to 2004, despite the introduction of several new efficacious therapies. This may be explained by the limitations of the current treatment options, poor access to healthcare, or medication noncompliance, as well as delayed diagnosis or treatment [28] . Timely diagnosis of lupus nephritis is still a challenge. The gold standard for diagnosis is renal biopsy which can be associated with significant morbidity, as well as inadequacies due to the 'blind'-nature of the procedure. Furthermore, a one-time diagnosis is often not sufficient, as the histopathology can change over time and therapy needs to be tailored appropriately. As serial biopsies are not usually done and current markers such as proteinuria have proved to be lacking [29, 30] , a more accurate, yet not invasive, diagnostic method is sought after.
The pathogenesis of lupus nephritis is now known to involve multiple mediators, and the [36] [37] [38] [39] [40] . Furthermore, in an effort to cast an even wider net, more comprehensive methods are now being used to identify such biomarkers, including microarray chips [38] [39] [40] , proteomics [41] , and combinations of markers that may together reflect disease activity more accurately than each component in isolation [42 & ,43,44,45 & ]. Several of the studied biomarkers are quite promising and may even prove to have therapeutic potential, as in many of the cases it is presumed that the biomarker is directly related to the pathogenesis of the disease (rather than just merely a side-product of the inflammatory process). As mentioned previously, TWEAK/Fn14 interactions play a role in lupus nephritis, and their neutralization has been shown to ameliorate disease progression. Several recent studies [46] [47] [48] have confirmed prior reports that urinary TWEAK levels reflect renal disease activity and correlate well with other potential biomarkers, such as MCP-1. Although most publications highlight biomarkers that correlate with some aspect of disease status, Treamtrakanpon et al. [49] provided evidence that the serum levels of the cytokine APRIL (a proliferation-inducing ligand) could potentially predict treatment resistance -a finding which, if validated, could be critical in therapy decisions for individual lupus nephritis patients.
Whereas prior microarray studies on peripheral blood mononuclear cells of SLE patients showed differential miRNA expression between patients and healthy controls [50] , more specific studies [38] [39] also indicated differential expression of miRNAs between lupus nephritis and non-lupus nephritis SLE patients. Via a similar microarray method, miR-126 was found to be upregulated in CD4 þ T cells of patients with SLE. At the same time, its levels were inversely associated with the CD4 þ T cell expression of DNA methyltransferase 1, a gene expression modulator that suppresses certain genes by the methylation of their promoter regions [51] . DNA methyltransferase 1 in lupus patients has reduced enzymatic activity, likely leading to T cell DNA hypomethylation which is generally associated with a permissive transcriptional environment. Indeed, T cell DNA hypomethylation levels correlate with SLE disease activity, suggesting an epigenetic factor in the development of SLE [52,53 & ]. Two separate studies have recently demonstrated the biomarker potential of urinary T cell levels. In a primarily cross-sectional study comparing 147 SLE patients (both lupus nephritis and nonlupus nephritis), 31 þ T cells and lupus nephritis activity, with excellent discrimination between active and nonactive lupus nephritis patients (area under the curve (AUC) 0.99). Furthermore, urinary CD4 þ T levels were higher in patients with proliferative disease (class IV and IV/V) compared with class I or pure class V. Similarly, in a smaller-scale study of urinary CD8 þ cells levels comparing 22 active lupus nephritis patients with 24 non-lupus nephritis SLE patients, Dolff et al. [31] showed good correlation with disease activity. The main clinical use for urinary CD8 þ cells may be to distinguish between patients with active lupus nephritis and those with a recent history of lupus nephritis but no current activity, as proteinuria may not be sensitive enough in this patient population to diagnose an early flare.
The fact that in each individual lupus nephritis patient there are likely multiple, distinct molecular pathways that are activated makes the likelihood of finding one unifying biomarker quite low. This has led many researchers to look for a combination of biomarkers, with the thought that the whole will be bigger (and more accurate) than the sum of its parts. Thus, Sui et al. [44] in a large retrospective study, including 589 SLE patients, found that simultaneous positivity for anti-DNA, antinucleosome, and antihistone antibodies was associated with a higher proportion of proliferative renal lesions (class IIIþIV) and a higher rate of recurrence and poor renal outcome. Brunner et al. [42 & ] analyzed multiple candidate urinary biomarkers in lupus nephritis patients that underwent renal biopsies, and compared them with specific histologic features. They found that different biomarker combinations reflect different specific tissue changes: the combination of monocyte chemotactic protein-1(MCP-1), a 1 -acid glycoprotein, ceruloplasmin, and protein:creatinine ratio was useful in reflecting lupus nephritis activity (AUC 0.85); MCP-1, neutrophil gelatinase-associated lipocalin, and creatinine clearance were best at predicting lupus nephritis chronicity (AUC 0.83); and the combination of MCP-1, a 1 -acid glycoprotein, transferrin, creatinine clearance, and C4 proved to be a good diagnostic tool for membranous lupus nephritis (AUC 0.75).
THERAPIES
Recent years have been quite exciting in terms of therapeutic advancements in SLE in general and lupus nephritis in particular. Although traditional treatments such as corticosteroids and immunosuppressants are nonspecific and associated with numerous side-effects, we are now seeing a rise in target-oriented therapies with promising prospects [54 && ,55
As the pathogenesis of the disease continues to be elucidated, many specific targets are being singled out for therapy, and conventional treatment protocols are being enhanced [57 & ].
Depletion of immune cells
The most talked-about B cell depletion drug in recent years has been rituximab. It is a monoclonal chimeric anti-CD20 mAb, targeting mature B cells, but not plasma cells [58] . As SLE is characterized by the loss of B cell tolerance and production of antibodies to self-antigens, the rationale behind depleting self-antigen presenting cells, as well as the precursors to the autoantibody-secreting cells, is apparent. In addition, as B cells also play a role in T cell activation and cytokine production, their depletion can affect different aspects of SLE pathogenesis [59 & ]. Indeed, there were multiple smallscale open-label studies that have demonstrated the efficacy of rituximab in refractory SLE [60 && ]. This explains the disappointment following the publication of results from two large randomized control trials: Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) [61] and Lupus Nephritis Assessment with Rituximab (LUNAR) [62] , which failed to demonstrate benefit from rituximab in renal and nonrenal lupus when added to the standard-of-care regimen. However, debate continues regarding the implication of these studies [63 & ,64 & ], which may have been problematic in terms of their endpoint definitions, lack of power to demonstrate the prespecified endpoints, and the background regimens being too aggressive to prove added benefits from additional drugs. Importantly, guidelines from both the American College of Rheumatology [65] and the European League against Rheumatism [66] support the use of rituximab in the treatment of refractory lupus nephritis. Of note, recently Condon et al. [67 & ] demonstrated a steroidsparing effect of rituximab in an observational study in which 50 lupus nephritis patients were treated with rituximab and low-dose mycophenolate mofetil. Good disease control was achieved, although at the same time only two patients required oral steroids after 2 years of follow up.
One explanation for the negative results in the Rituximab trials may be that the antibody-secreting cells driving the kidney inflammation in lupus nephritis are long-lived plasma cells, which do not display CD20 and are, therefore, not targeted by the drug [7 && ,68] . Interestingly, it has recently been shown by Wang et al. [69] that a prolonged course of rituximab in NZB/NZW F1 mice markedly reduced kidney plasma cell levels, as well as decreased antibody levels and disease activity significantly better than a short course of the drug. It is as-yet unknown how this plasma cell depletion was brought about by rituximab, but one reasonable explanation may be that the prolonged course led to an extended period of B cell depletion, which in turn prevented ongoing maturation and differentiation of B cells into plasma cells [69] . Although this effect of rituximab on plasma cells needs to be further studied, there are reports regarding the efficacy of a plasma-cell depletor, bortezomib, in lupus nephritis [70] [71] [72] . Bortezomib inhibits the proteasome within plasma cells, resulting in inability to degrade misfolded proteins, which eventually leads to apoptosis. Although bortezomib has shown promise in reducing disease activity and decreasing autoantibody concentrations while increasing complement levels [71] , this drug has been associated with serious neurotoxicity [73] .
Cytokine modulation
As mentioned previously, several cytokines and chemokines are thought to play major roles in the triggering and perpetuation of inflammation in SLE, and may prove to be effective therapeutic targets. Of those, one of the most clinically relevant is BAFF, which promotes the formation and survival of memory B cells and antibody-secreting plasmablasts [74 && ]. Belimumab, a BAFF inhibitor, has been the first new treatment to be approved by the United States Food and Drug Administration for nonrenal SLE in 50 years. In two phase III randomized controlled trials, BLISS 52 [75] and BLISS 76 [76] , belimumab demonstrated added benefit as compared with placebo when used together with standard therapy. A posthoc analysis of the trials to determine the drug's efficacy in lupus nephritis also showed a trend toward increased response in the belimumab group compared with placebo [77] . Currently, a phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Belimumab in lupus nephritis is underway (ClinicalTrials.gov Identifier: NCT01639339).
Interestingly, Rovin and Parikh [78 && ] discuss the possibility of achieving the best disease control by stepwise use of the different agents, according to the chronology of the pathogenesis of lupus nephritis. As the major, most immediate culprits in the renal inflammation are most likely the autoantibodyproducing plasma cells, it may be useful to first administer a course of a proteasome inhibitor in order to deplete the plasma cells, followed by B cell depletion to prevent further differentiation into plasma cells. Finally, B cell depletion is associated with an increase in BAFF, likely as a reaction to the reduced B cell counts. Increased BAFF likely induces more autoreactive B cells once the B cells are reconstituted posttreatment. Therefore, the use of BAFFinhibitors such as belimumab at the time of B cell depletion may be beneficial in preventing the return of autoreactive B cells and sustaining remission [78 && ]. This idea of tailoring therapy to defined targets at specific points in time is intriguing, and may herald future target-specific and pathogenesisdirected management of complicated diseases.
CONCLUSION
If lupus nephritis were a soap opera and we had to summarize the events of the past few seasons, we could say that we watched some interesting developments: good guys (maybe) going bad (rituximab), the introduction of a whole new set of characters (long-lived plasma cells in the renal interstitium, microRNAs as biomarkers and potential therapeutic targets), and the development of a passionate, yet intriguing, long-term relationship (treatment with biologics, with its ups and downs). We have much to look forward to in the 'episodes' ahead. 
